These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 33285053

  • 1. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
    Dong SQ, Wang TM, Zhang JB, He YQ, Xue WQ, Wu ZY, Yang DW, Cao LJ, Huang JW, Li XZ, Zhang PF, Zheng XH, Jia WH.
    Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
    [Abstract] [Full Text] [Related]

  • 2. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
    Hamzic S, Kummer D, Froehlich TK, Joerger M, Aebi S, Palles C, Thomlinson I, Meulendijks D, Schellens JHM, García-González X, López-Fernández LA, Amstutz U, Largiadèr CR.
    Pharmacol Res; 2020 Feb; 152():104594. PubMed ID: 31838077
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer.
    Ntavatzikos A, Spathis A, Patapis P, Machairas N, Peros G, Konstantoudakis S, Leventakou D, Panayiotides IG, Karakitsos P, Koumarianou A.
    World J Gastroenterol; 2017 Aug 28; 23(32):5913-5924. PubMed ID: 28932083
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity.
    Ioannou C, Ragia G, Balgkouranidou I, Xenidis N, Amarantidis K, Koukaki T, Biziota E, Kakolyris S, Manolopoulos VG.
    Pharmacogenomics; 2021 Jul 28; 22(11):669-680. PubMed ID: 34100299
    [Abstract] [Full Text] [Related]

  • 11. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
    Shahrokni A, Rajebi MR, Saif MW.
    Clin Colorectal Cancer; 2009 Oct 28; 8(4):231-4. PubMed ID: 19822515
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M, Huitema AD, Boot H, Cats A, Doodeman VD, Smits PH, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2015 Apr 28; 75(4):763-72. PubMed ID: 25677447
    [Abstract] [Full Text] [Related]

  • 16. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
    Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S.
    Chem Res Toxicol; 2016 Oct 17; 29(10):1591-1601. PubMed ID: 27631426
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
    Chao YL, Anders CK.
    Clin Breast Cancer; 2018 Jun 17; 18(3):e301-e304. PubMed ID: 28899623
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.
    King TL, Voon PJ, Yuen KH, Mohamed Noor DA.
    Support Care Cancer; 2024 May 14; 32(6):345. PubMed ID: 38743316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.